The impact of abrocitinib on vaccine-induced immune responses in adolescents with moderate-to-severe atopic dermatitis undergoing routine tetanus, diphtheria, and pertussis vaccination in phase 3 JADE TEEN

被引：0
|
作者：
Cork, Michael
Eichenfield, Lawrence
Flohr, Carsten
Bangert, Christine
Barbarot, Sebastien
Rojo, Ricardo
Chan, Gary
Zhang, Fan
Feeney, Claire
Valdez, Hernan
机构：
来源：
ALLERGY AND ASTHMA PROCEEDINGS | 2024年 / 45卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：4
相关论文
共 33 条
  • [21] Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab Treatment: An Analysis of JADE-EXTEND, a Phase 3 Long Term Extension Study
    Shi, Vivian Y.
    Bhutani, Tina
    Deleuran, Mette
    Fonacier, Luz
    Shumack, Stephen
    Zhang, Fan
    Cameron, Michael C.
    Chan, Gary
    Valdez, Hernan
    Yin, Natalie
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 77 - 78
  • [22] Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis
    Merola, Joseph F.
    Bagel, Jerry
    Almgren, Peter
    Ropke, Mads A.
    Lophaven, Katja W.
    Vest, Natacha Strange
    Grewal, Parbeer
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (01) : 71 - 78
  • [23] Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
    Blauvelt, Andrew
    Silverberg, Jonathan, I
    Lynde, Charles W.
    Bieber, Thomas
    Eisman, Samantha
    Zdybski, Jacek
    Gubelin, Walter
    Simpson, Eric L.
    Valenzuela, Fernando
    Criado, Paulo Ricardo
    Lebwohl, Mark G.
    Feeney, Claire
    Khan, Tahira
    Biswas, Pinaki
    DiBonaventura, Marco
    Valdez, Hernan
    Cameron, Michael C.
    Rojo, Ricardo
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (01) : 104 - 112
  • [24] Abrocitinib in the treatment of moderate-to-severe atopic dermatitis refractory to dupilumab treatment: An analysis of JADE-EXTEND, a phase 3 long-term extension study
    Shi, Vivian
    Bhutani, Tina
    Deleuran, Mette
    Fonacier, Luz
    Shumack, Stephen
    Zhang, Fan
    Cameron, Michael C.
    Chan, Gary
    Valdez, Hernan
    Yin, Natalie
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB36 - AB36
  • [25] Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
    Simpson, Eric L.
    Sinclair, Rodney
    Forman, Seth
    Wollenberg, Andreas
    Aschoff, Roland
    Cork, Michael
    Bieber, Thomas
    Thyssen, Jacob P.
    Yosipovitch, Gil
    Flohr, Carsten
    Magnolo, Nina
    Maari, Catherine
    Feeney, Claire
    Biswas, Pinaki
    Tatulych, Svitlana
    Valdez, Hernan
    Rojo, Ricardo
    LANCET, 2020, 396 (10246): : 255 - 266
  • [26] Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study
    Gooderham, Melinda J.
    Weidinger, Stephan
    Simpson, Eric L.
    Deleuran, Mette
    Gold, Linda F. Stein
    Farooqui, Saleem A.
    Biswas, Pinaki
    Chan, Gary
    Guler, Erman
    Koppensteiner, Herwig
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II32 - II33
  • [27] Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study
    Reich, Kristian
    Silverberg, Jonathan I.
    Papp, Kim A.
    Deleuran, Mette
    Katoh, Norito
    Strober, Bruce
    Beck, Lisa A.
    de Bruin-Weller, Marjolein
    Werfel, Thomas
    Zhang, Fan
    Biswas, Pinaki
    DiBonaventura, Marco D.
    Chan, Gary
    Johnson, Susan
    Farooqui, Saleem A.
    Kerkmann, Urs
    Clibborn, Claire
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (10) : 2056 - 2066
  • [28] Long-term efficacy of abrocitinib up to 96 weeks in adults with moderate-to-severe atopic dermatitis stratified by age: a post hoc analysis of the JADE EXTEND phase 3 trial
    Alexis, Andrew F.
    Deleuran, Mette
    Silverberg, Jonathan, I
    Gooderham, Melinda J.
    Farooqui, Saleem A.
    Chan, Gary
    Koppensteiner, Herwig
    Biswas, Pinaki
    Watkins, Melissa
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [29] Protocol for an ongoing, phase III multicentre, long-term extension study investigating the long-term safety and efficacy of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE EXTEND)
    Simpson, E. L.
    Reich, K.
    Silverberg, J. I.
    Nasir, A.
    Criado, P. R.
    Biswas, P.
    Koppensteiner, H.
    Fan, D.
    Rojo, R.
    Farooqui, S. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E159 - E159
  • [30] Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study
    Reich, K.
    Silverberg, J. I.
    Papp, K. A.
    Deleuran, M.
    Katoh, N.
    Strober, B.
    Beck, L. A.
    de Bruin-Weller, M.
    Werfel, T.
    Zhang, F.
    Biswas, P.
    DiBonaventura, M. D.
    Chan, G.
    Farooqui, S. A.
    Kerkmann, U.
    Clibborn, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (10) : 2047 - 2055
1234